Correlation between lymphocyte counts and PD-L1 immune-related adverse events
Journal of Oncology Pharmacy Practice
Published online on January 23, 2026
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
IntroductionImmune checkpoint inhibitors have improved outcomes for solid tumors but are associated with immune-related adverse events (irAEs). Literature suggests that patients with an absolute lymphocyte count (ALC) ≥ 2000 cells/mm3 prior to treatment ...
IntroductionImmune checkpoint inhibitors have improved outcomes for solid tumors but are associated with immune-related adverse events (irAEs). Literature suggests that patients with an absolute lymphocyte count (ALC) ≥ 2000 cells/mm3 prior to treatment ...